RT Journal Article
SR Electronic
T1 Viral RNA level, serum antibody responses, and transmission risk in discharged COVID-19 patients with recurrent positive SARS-CoV-2 RNA test results: a population-based observational cohort study
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.07.21.20125138
DO 10.1101/2020.07.21.20125138
A1 Chao Yang
A1 Min Jiang
A1 Xiaohui Wang
A1 Xiujuan Tang
A1 Shisong Fang
A1 Hao Li
A1 Le Zuo
A1 Yixiang Jiang
A1 Yifan Zhong
A1 Qiongcheng Chen
A1 Chenli Zheng
A1 Lei Wang
A1 Shuang Wu
A1 Weihua Wu
A1 Hui Liu
A1 Jing Yuan
A1 Xuejiao Liao
A1 Zhen Zhang
A1 Yiman Lin
A1 Yijie Geng
A1 Huan Zhang
A1 Huanying Zheng
A1 Min Wan
A1 Linying Lu
A1 Xiaohu Ren
A1 Yujun Cui
A1 Xuan Zou
A1 Tiejian Feng
A1 Junjie Xia
A1 Ruifu Yang
A1 Yingxia Liu
A1 Shujiang Mei
A1 Baisheng Li
A1 Zhengrong Yang
A1 Qinghua Hu
YR 2020
UL http://medrxiv.org/content/early/2020/07/26/2020.07.21.20125138.abstract
AB Background Managing discharged COVID-19 (DC) patients with recurrent positive (RP) SARS-CoV-2 RNA test results is challenging. We aimed to comprehensively characterize the viral RNA level and serum antibody responses in RP-DC patients and evaluate their viral transmission risk.Methods A population-based observational cohort study was performed on 479 DC patients discharged from February 1 to May 5, 2020 in Shenzhen, China. We conducted RT-qPCR, antibody assays, neutralisation assays, virus isolation, whole genome sequencing (WGS), and epidemiological investigation of close contacts.Findings Of 479 DC patients, the 93 (19%) RP individuals, including 36 with multiple RP results, were characterised by young age (median age: 34 years, 95% confidence interval [CI]: 29–38 years). The median discharge-to-RP length was 8 days (95% CI: 7–14 days; maximum: 90 days). After readmission, RP-DC patients exhibited mild (28%) or absent (72%) symptoms, with no disease progression. The viral RNA level in RP-DC patients ranged from 1·9–5·7 log10 copies/mL (median: 3·2, 95% CI: 3·1–3·5). At RP detection, the IgM, IgG, IgA, total antibody, and neutralising antibody (NAb) seropositivity rates in RP-DC patients were 38% (18/48), 98% (47/48), 63% (30/48), 100% (48/48), and 91% (39/43), respectively. Regarding antibody levels, there was no significant difference between RP-DC and non-RP-DC patients. The antibody level remained constant in RP-DC patients pre- and post-RP detection. Virus isolation of nine representative specimens returned negative results. WGS of six specimens yielded only genomic fragments. No clinical symptoms were exhibited by 96 close contacts of 23 RP-DC patients; their viral RNA (96/96) and antibody (20/20) test results were negative. After full recovery, 60% of patients (n=162, 78 no longer RP RP-DC and 84 non-RP-DC) had NAb titres of ≥1:32.Interpretation RP may occur in DC patients following intermittent and non-stable excretion of low viral RNA levels. RP-DC patients pose a low risk of transmitting SARS-CoV-2. An NAb titre of ≥ 1:32 may provide a reference indicator for evaluating humoral responses in COVID-19 vaccine clinical trials.Funding Sanming Project of Medicine in Shenzhen, China National Science and Technology Major Projects Foundation, Special Foundation of Science and Technology Innovation Strategy of Guangdong Province of China, and Shenzhen Committee of Scientific and Technical Innovation grants.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis research was supported by Sanming Project of Medicine in Shenzhen (No. SZSM201811071), the China National Science and Technology Major Projects Foundation (No. 2017ZX10303406), Special Foundation of Science and Technology Innovation Strategy of Guangdong Province of China (No. 2020B1111340077), and a Shenzhen Committee of Scientific and Technical Innovation grant (No. JCYJ20180508152244835).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the Ethics Committee of Shenzhen CDC (QS2020060007). As data collection is part of the public health investigation of an emerging outbreak, individual informed consent was waived.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll the data are available